114 results about "Respiratory virus" patented technology

The invention discloses a compound derivative represented by a formula I or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt thereof. According to the application of a double protection strategy, diversified carrier fragments are introduced to 5-hydroxyl and hydroxylamine in N4-hydroxycytidine molecules, the N4-hydroxycytidine prodrug is invented, the affinity of lung cell membranes (phospholipid membranes) is improved, and the physicochemical properties of the drug are made to meet the requirements of the physiological environment of lung tissue. Therefore, the compound disclosed by the invention has a wide application prospect in the aspect of broad-spectrum respiratory virus resistance. # imgabs0 #

The present disclosure relates to compositions and methods for vaccinating a subject against a variety of SARS-CoV-2 variants and other respiratory viruses, the compositions and methods involve preparing and delivering extracellular vesicles expressing on its surface an engineered spike protein, an engineered nucleocapsid protein, an engineered hemagglutinin protein, and / or an engineered respiratory syncytial virus pre-fusion or fusion (RSV F) protein. The invention also relates to compositions and methods for designing, preparing, making, formulating and / or using spike display, nucleocapsid display, hemagglutinin display and / or RSV F display vesicle vaccines, the spike display, nucleocapsid display, hemagglutinin display, and / or RSV F display vesicle vaccines are designed to elicit potent humoral and cellular immune responses against a variety of respiratory viruses and variants.

The invention relates to methods and kits for detecting a virus, e.g., a respiratory virus such as a coronavirus, in a biological sample. The invention also relates to methods and kits for detecting and / or quantifying biomarkers, e.g., antibody biomarkers against a viral antigen; inflammatory and / or tissue damage response biomarkers; and / or extracellular vesicles in response to a viral infection.

The application discloses a method for producing pectin oligosaccharides by microbial degradation of pomace and application thereof. The method comprises the following steps: adding microbacterium A5 to a culture medium containing pomace to perform fermentation to obtain a fermentation liquor, performing fractional pressing filtration and filter sterilization on the fermentation liquor, performing ethanol precipitation to extract a pectin crude product, removing protein, performing ion exchange chromatography, dialysis desalting, freeze drying and the like to purify two pectin oligosaccharides POS-1 and POS-2 with a purity greater than 95%; the pectin oligosaccharides POS-1 and POS-2 have strong scavenging capacity on hydroxyl radicals and DPPH free radicals and the capacity of inhibiting the activity of respiratory RNA viruses such as influenza virus H1N1 and respiratory syncytial virus RSV, and can be applied to medicines or health foods.

The present invention relates to a viral strain derived from a human metapneumovirus (hMPV) strain having a genomic sequence represented by sequence SEQ ID NO: 1 wherein the genomic sequence comprises the following genetic modifications: (i) inactivating an endogenous gene encoding an SH protein and / or a G protein, and (ii) the presence of an exogenous sequence encoding at least one extracellular domain of an F protein of a human respiratory syncytial virus (hRSV), the domain is of a wild type or mutant.

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention provides a Raman enhanced nano-label based on a polydopamine core-shell structure, a preparation method and application of the Raman enhanced nano-label in immunochromatography, and relates to the technical field of immunochromatography. The Raman enhanced nano-label based on the polydopamine core-shell structure sequentially comprises a PDA microsphere core, a PEI layer and a gold and silver nano-particle layer from inside to outside, the gold and silver nanoparticle layer is gold and silver nanoparticles with a core-shell structure; the gold and silver nanoparticle layer is connected with a Raman signal molecule DTNB, and a terminal carboxyl group of the Raman signal molecule DTNB is coupled with a capture antibody of an H1N1 virus or a capture antibody of an SARS-CoV-2 virus. The nano-label has colorimetric and SERS enhanced activity at the same time, has the advantages of rich hot spots, high stability, excellent optical performance and the like, is used for an immunochromatography sensor to detect two respiratory viruses at the same time, adopts qualitative and quantitative dual-mode detection, and improves the detection flexibility, sensitivity and accuracy.

The utility model belongs to the field of medical instruments, and particularly relates to a respiratory virus sampling device which comprises a handle, the interior of the handle is connected with a separation assembly, and the left end of the handle is connected with a sampling assembly; through the structural design of the separating assembly, after sampling is finished, the two operating rods are pushed from the right end of the handle to the middle, the operating rods can be driven to slide towards the middle along the connecting rod, so that the spring is driven to be compressed, the limiting rod is separated from the limiting groove, the handle can be directly separated from the sampling rod, and operations such as breaking are not needed; the device has the advantages of simple structure, convenience and rapidness in separation and no splashing of liquid in a sample bottle due to uneven force, and solves the problems that a sample is possibly damaged due to the fact that the breaking force is possibly difficult to control in operation when a sampling swab head is taken down in a breaking manner in a comparison patent. And the liquid in the sample bottle can be splashed due to the applied force during breaking, so that the sampling safety is easily influenced.

The present application relates to the technical field of nucleic acid detection, in particular to a RNA pathogen chemiluminescence detection method based on nucleic acid structure and sequence characteristics. The present application provides a pathogen RNA rapid detection technology based on the reporter molecule cyclization combined with rolling circle amplification according to the secondary structure and sequence characteristics of RNA, which is suitable for high-sensitivity and high-specificity detection of RNA pathogens such as respiratory viruses. The present application innovatively combines the target structure characteristics with sequence specificity, breaks through the traditional sequence-dependent isothermal amplification technology, realizes the highly specific reporter molecule cyclization, significantly improves the detection reliability, and does not require complex instruments. After the swab sample is collected, the pathogen RNA is rapidly released by using a nucleic acid releasing agent, without complex purification steps, and the reading can be realized through a common chemiluminescence instrument, which is suitable for primary site detection.

Some aspects of the disclosure relate to vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses as well as methods of using the vaccines. Also described are combination vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses and other respiratory viruses (e.g., respiratory syncytial viruses and coronaviruses), as well as methods of using the vaccines.

Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and / or preventing conditions such as, for example, those caused by any viral family causing respiratory viral disease, including specifically coronaviruses and influenza viruses.

The invention relates to the technical field of nucleic acid detection, in particular to an RNA pathogen chemiluminescence detection method based on a nucleic acid structure and sequence characteristics. The invention provides a pathogen RNA rapid detection technology which is based on RNA secondary structure and sequence characteristic reporter molecule cyclization and is combined with rolling circle amplification, and is suitable for high-sensitivity and high-specificity detection of RNA pathogens such as respiratory viruses. Target structure characteristics and sequence specificity are creatively combined, a traditional sequence-dependent isothermal amplification technology is broken through, high-specificity reporter molecule cyclization is achieved, the detection reliability is remarkably improved, complex instruments are not needed, after swab samples are collected, pathogen RNA is rapidly released through a nucleic acid releasing agent, complex purification steps are not needed, and the method is suitable for large-scale popularization and application. And reading can be realized through a common chemiluminiscence instrument, and the method is suitable for base-level field detection.

The invention relates to a quinoline triazole compound and application thereof. The quinoline triazole compound has the structural characteristics as shown in formula I, and can effectively treat diseases caused by respiratory viruses such as influenza.

A vaccine composition comprising one or more proteins expressed on the surface of a respiratory virus or bacterium and one or more pharmaceutically acceptable excipient, wherein the composition is in particulate form having a mean particle size in a range of from 2 to 50 μm. The protein is contained in the composition in its correctly folded three-dimensional structure.

The application relates to the field of microorganism detection, in particular to a respiratory virus rapid detection kit based on ZIF-8 material and a preparation method, wherein the kit comprises a virus collecting device, an exhalation cylinder and a ZIF-8 membrane, the ZIF-8 membrane is detachably arranged in the exhalation cylinder, the ZIF-8 membrane comprises a chitosan layer, the chitosan layer is uniformly distributed with ZIF-8 material, virus particles in the exhaled gas of a tester through the exhalation cylinder are adsorbed, a sample processing device comprises a processing liquid, the processing liquid elutes and lyses the virus particles adsorbed by the ZIF-8 material distributed on the chitosan layer, and a virus processing liquid is obtained, a detection reagent is used for detecting the virus processing liquid and giving a detection result, sampling is simple and rapid, the detection can be completed without the participation of professionals, sampling efficiency is higher, and the detection sensitivity is effectively improved.

1. Name of the design product: Preservation box (for respiratory virus sampling). 2. Use of the design product: Sample preservation for respiratory virus sampling. 3. Design key points of the design product: Lies in the shape. 4. Picture or photograph that best shows the design key points: Perspective view.

The invention belongs to the technical field of biology, and discloses a monoclonal antibody capable of simultaneously recognizing multiple pedigree of porcine reproductive and respiratory syndrome virus GP5 protein. The invention discloses a recombinant protein. The recombinant protein is formed by repeatedly connecting two short peptides in series. The GP5 protein is a basis for dividing a PRRSV pedigree, the GP5 protein is taken as a research object, two regions with relatively strong immunogenicity on amino acid of the GP5 protein are repeatedly connected in series, and the two regions are further connected in series with a tag sequence or a Foldon oligopeptide to obtain a recombinant protein. The recombinant protein is used as an immunogen, and a monoclonal antibody capable of simultaneously identifying GP5 proteins of a plurality of pedigree (including pedigree 1, pedigree 3, pedigree 5 and pedigree 8) of PRRSV is prepared and screened.

In one aspect, provided herein are methods for preventing and / or treating respiratory virus diseases (e.g., moderate to severe respiratory virus diseases) comprising administering to a subject (e.g., a human subject) hypersialylated intravenous immunoglobulin (IVIg), a protein comprising a sialylated IgG Fc region, or a protein comprising a modified IgG Fc region that mimics IgG Fc sialylation. In another aspect, provided herein are methods for improving lung function or preserving lung function in a subject with a respiratory virus disease (e.g., moderate to severe respiratory virus diseases) comprising administering to a subject (e.g., a human subject) hypersialylated intravenous immunoglobulin (IVIg), a protein comprising a sialylated IgG Fc region, or a protein comprising a modified IgG Fc region that mimics IgG Fc sialylation.

The present invention provides the use of liriope muscari saponin C in the preparation of anti-respiratory virus drugs, belonging to the field of antiviral drug preparation. The liriope muscari saponin C of the present invention shows different degrees of inhibitory effects on influenza virus (H1N1) and novel coronavirus (SARS-CoV-2), showing good antiviral application prospects. Liriope muscari saponin C effectively inhibits the replication of influenza virus and the infection of SARS-CoV-2 to host by inhibiting the nuclear translocation of influenza virus vRNP complex and the binding of SARS-CoV-2 S protein and ACE2.

According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

Disclosed in the present invention are a compound derivative represented by formula I or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomer thereof, or a pharmaceutically acceptable salt thereof. On the basis of the application of a dual-protection strategy, diverse carrier fragments are introduced at the 5-hydroxyl group and hydroxylamine group of the N4-hydroxycytidine molecule to develop an N4-hydroxycytidine prodrug. Such a modification enhances the affinity for a pulmonary cell membrane (phospholipid membrane), rendering the physicochemical properties of the drug suitable for the physiological environment of lung tissue. Therefore, the compound of the present invention has a broad application prospect in the aspect of broad-spectrum anti-respiratory viruses.

The present application relates to the field of molecular biology detection, in particular to a fluorescent PCR kit and a detection method for respiratory virus detection. The present application constructs specific primer groups and probes for detecting respiratory viruses, including influenza A virus, influenza B virus, human parainfluenza virus type I, human parainfluenza virus type II, human parainfluenza virus type III, respiratory syncytial virus and metapneumovirus. Through a matching PCR system, the simultaneous detection of multiple respiratory pathogens is realized in a single-color detection channel by using the melting curve and the characteristic peak of the melting temperature as indicators. The present application at least doubles the existing fluorescent PCR detection throughput, has low cost, short time consumption, greatly improves the detection efficiency, and can be widely used for mixed detection and analysis of multiple pathogens. The detection results can be further used for assisting clinical diagnosis and treatment.

The invention relates to a method and equipment for rapidly killing respiratory viruses by spatially spraying hydroxyl free radical droplets, and the method comprises the following steps: introducing oxygen O2 into an oxygen plasma generation source, and applying high-frequency and high-voltage excitation to the oxygen plasma generation source to generate high-concentration oxygen active particles; oxygen active particle gas is injected into the jet mixer, a large number of ultra-fine bubbles are generated through the water jet cavitation effect, OH is efficiently generated at the instant high temperature and high pressure of explosion of the ultra-fine bubbles and under the action of pressure shock waves of backfilling holes, and then the OH flows into the second-stage baffling mixing and dissolving device to generate a high-concentration OH solution; the OH solution is sheared by high-pressure jet flow of the spray head to form OH liquid drops, and the liquid drops are contacted, collided, broken and spread to instantly kill pathogenic microorganisms including respiratory viruses; the intelligent control system performs real-time state sensing and intelligent control, fault diagnosis, prediction and early warning, cloud service and remote monitoring.

The invention discloses application of radix glehniae polysaccharide in preventing and treating respiratory syncytial virus, and belongs to the technical field of biological medicine. The research finds that the radix glehniae polysaccharide in the radix glehniae can play a role in inhibiting the respiratory syncytial virus and can be used as a specific active ingredient for preventing and treating the respiratory syncytial virus for the first time. The research result of the invention overcomes the technical blind area that the overall efficacy of traditional Chinese medicine components cannot be attributed to specific components, accurately positions that the radix glehniae polysaccharide can play an anti-RSV role when being independently used, and provides a new target for designing a targeted RSV inhibitor and developing a combined medication strategy covering various respiratory viruses.

A vaccine composition comprising one or more proteins expressed on the surface of a respiratory virus or bacterium and one or more pharmaceutically acceptable excipient, wherein the composition is in particulate form having a mean particle size in a range of from 2 to 50 μm. The protein is contained in the composition in its correctly folded three-dimensional structure.

The invention discloses a phoebe zhennan water-soluble extract as well as an extraction method and application thereof, and belongs to the technical field of medicine extraction. The method comprises the following steps: S1, crushing a phoebe zhennan raw material, adding 6 times of water, extracting twice, 1 hour each time, and combining filtrates; s2, concentrating the filtrate obtained in the step S1 under reduced pressure until the volume is 1: 1, standing at low temperature, and taking supernate; and S3, centrifuging the supernate obtained in S2, discarding the precipitate, concentrating under reduced pressure, and drying at low temperature to obtain the phoebe zhennan water-soluble extract. The invention discloses a phoebe zhennan water-soluble extract and an extraction method and application thereof. The phoebe zhennan water-soluble extract has efficient broad-spectrum antiviral activity and can effectively inhibit respiratory virus activity.

The utility model discloses a medical cotton swab portable storage device which comprises a main body box, an avoiding hole is formed in the top face of the main body box, medical cotton swabs used for screening and collecting respiratory viruses can be conveniently carried through a storage assembly, when the medical cotton swabs need to be used, a second baffle plate is pushed, and the medical cotton swabs can be conveniently stored. A single cotton swab can be pushed out from the interior of the main body box by pushing a pushing frame, and after the pushed-out cotton swab is taken out, a second baffle plate and the pushing frame are reset immediately, so that the other medical cotton swabs are prevented from being polluted after being in contact with other articles; the cotton swabs subjected to screening and collecting can be put into the isolation box by pulling the isolation plate, and the cotton swabs in the isolation box can be shielded and isolated by pushing the isolation plate through a fourth spring after the isolation plate is loosened, so that the situation that the cotton swabs carrying viruses make contact with other objects, and consequently secondary infection is caused is avoided.

The invention provides a sensor for multichannel respiratory virus impedance detection and a detection method thereof. The synchronous detection of four respiratory viruses by the single-electrode chip is realized by electrodepositing nano-gold particles on the surface of a screen-printed carbon electrode and constructing a carboxyl self-assembled single layer, and fixing different virus specific antibodies on the surfaces of different working electrodes by adopting EDC / NHS (Ethylene Diamine Chloride / N-Hydroxysuccinimide). And recording an electrochemical impedance spectrum by using a red oxidation-reduction probe, and carrying out quantitative analysis based on total impedance change. The method has the advantages of high sensitivity, strong specificity, short detection period, low cost, suitability for on-site rapid screening and the like.

A high-sensitivity respiratory virus rapid detection device and method, the device includes a terahertz light source system, a respiratory virus test unit and a terahertz spectrum analysis unit. Wherein the respiratory virus test unit should produce a response according to the specific virus sample in different terahertz wave band, design corresponding terahertz field enhancement structure to improve the signal-to-noise ratio of the spectrum of the sample under the excitation of terahertz wave, so that the terahertz wave can produce obvious characteristic absorption spectrum after passing through the respiratory virus test unit, improve the sensitivity of terahertz wave spectrum detection, so as to obtain better respiratory virus detection effect.

The present disclosure relates to methods for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject in need thereof, the method comprising administering to the subject an anti-Type I interferon (anti-T1i) therapy that blocks the activity, function or production of Type I interferon (T1i) in the subject, wherein the anti-T1i therapy is administered to the subject infected with a respiratory virus that causes a delayed T1i response in the subject.